Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.15 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€24.02M

Enterprise Value€28.91

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.26

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth TrendSustained multi-year top-line recovery indicates strengthening commercial traction and market acceptance of implant platforms. Growing revenue helps absorb fixed costs, enable operating leverage, and create a clearer path to break-even if the trend persists and distribution/procedure adoption continues.

Improving Gross MarginA materially higher gross margin suggests improving product mix, pricing or cost control at the manufacturing level. Durable margin expansion raises the amount of revenue converting to contribution margin, supporting future operating margin improvement and reducing cash burn per incremental sale.

Recurring/Procedure-Linked Revenue ModelImplants and associated consumables create repeatable demand and platform stickiness with surgeons and hospitals. Durable procedure-linked revenue supports predictable reorder streams, upsell of compatible components, and customer lifetime value that can stabilize growth and margin over time.

Bears Say

Persistent LossesSustained negative net margins show the business has not yet converted top-line gains into profitability. Continued losses erode equity, increase refinancing risk, and mean management must either cut costs or secure external capital to fund operations, which can dilute shareholders or constrain strategic options.

Negative Cash GenerationOngoing negative operating and free cash flow forces reliance on external funding and limits reinvestment capacity. Even with improvement, persistent cash burn increases liquidity risk and may require frequent financing rounds, interrupting long-term investment in sales, R&D, or manufacturing scale-up.

High Leverage, Thin EquityA very small equity buffer and elevated debt load magnify solvency risk if losses continue. High leverage restricts financial flexibility, raises refinancing and covenant risk, and can limit the company's ability to pursue strategic initiatives or absorb operational shocks without dilutive or costly financing.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.15 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €24.02M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 45 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.